Attention:

Certain features of Sigma-Aldrich.com will be down for maintenance the evening of Friday August 18th starting at 8:00 pm CDT until Saturday August 19th at 12:01 pm CDT.   Please note that you still have telephone and email access to our local offices. We apologize for any inconvenience.

Magnetic Nanoparticles for Cancer Theranostics

   

Saumya Nigam,1 Lina Pradhan,2 and D. Bahadur*3
1IITB-Monash Research Academy, IIT Bombay, Powai, Mumbai, India
2Centre for Research in Nanotechnology & Science IIT Bombay, Powai, Mumbai, India 3Department of Metallurgical Engineering and Materials Science, IIT Bombay, Powai, Mumbai, India
Email: dhirenb@iitb.ac.in

Introduction

The recent emergence of a number of highly functional nanomaterials has enabled new approaches to the understanding, diagnosis, and treatment of cancer. Of these, a variety of functional magnetic nanoparticles, including superparamagnetic ferrite nanoparticles of iron, cobalt, manganese, and nickel have proven themselves as particularly beneficial for biomedical applications.1–6 In particular, multifunctional ferrofluids (MFs) are now being intensively studied in order to unlock their promise for future therapies.5,6

A ferrofluid is a suspension of magnetic nanoparticles which behaves as a “liquid magnet” under the presence of a permanent magnetic field. Ferrofluids can be easily modified to contain different surface functional groups of both biological and non-biological origin7,8 for the conjugation of therapeutic payloads and imaging molecules, enabling enhanced specificity in targeted therapeutics and diagnostics. Furthermore, MFs exhibit the unique capability to produce heat when exposed to an alternating magnetic field.9 Since cancer cells exhibit low tolerance for elevated temperatures (above 42 °C), it is expected that localized heat from MFs could be used for the targeted treatment of cancer cells (hyperthermia treatment).10–12 Magnetic hyperthermia can also be used to aid in the release of a therapeutic payload from MFs, resulting in enhanced release efficiency in the immediate tumor environment.

MFs exhibit a number of unique characteristics that have the potential to impart significant therapeutic advantages, including:

  • Aqueous colloidal stability with minimal particle agglomeration
  • Enhanced loading efficiencies as a platform for both hydrophilic and hydrophobic drugs
  • Encapsulation of multiple drugs in a single system
  • Triggered and controlled release of a drug at the target site under the influence of external stimuli like pH, temperature, AC magnetic field, and ultrasound
  • Appreciable biocompatibility and biodegradability
  • Rapid clearance by reticulo-endothelial system (RES) of the body
  • Reduction of circulating concentration of free drug, thereby reducing side effects
  • Minimization of multidrug resistance at the targeted tumor site
  • Simultaneous use for MR imaging and other diagnostic applications

Recently, we have developed a variety of iron oxide-based MF hybrid systems with different surface functionalization including dendrimers,13 lipids,14 hydrogels,15 bio-degradable polymers, citric acid,16 and silica.17 The surface functional groups allow multifunctionality in these iron oxidebased ferrofluids and make them thermo- and/or pH-responsive.13,14 The iron oxide based MFs are highly stable in aqueous conditions and have been successfully tested for the delivery of both hydrophilic and hydrophobic drugs, along with magnetic hyperthermia applications in cancer cell lines as well as in subcutaneous tumor models in mice. This article presents an overview of the therapeutic performance of following systems toward various cancer cell lines:

  • Stimuli-responsive magnetic nanohydrogels (MNHGs)
  • Tc-tuned magnetic nanovesicles
  • Dendrimer-functionalized magnetic nanoparticles
  • Thermo- and pH-responsive thin lipid layer coated mesoporous magnetic nanoassemblies (LMMNA)

These formulations have also been evaluated for their performance in dual mode cancer therapy, utilizing magnetic hyperthermia in synergy with chemotherapy, non-invasive MR imaging, and electrochemical biosensing. Some of these hybrid systems have been further explored for in vivo applications.

Stimuli-responsive Magnetic Nanohydrogels

Hydrogels are hydrophilic, crosslinked polymers existing in a colloidal gel state. Due to their tailorable physical, chemical, and biological properties, they have been tested in numerous biomedical applications. It has been shown that the encapsulation of ferrofluids within hydrogels can result in improved biomedical properties.18 For example, Lin et al. reported the delivery of chemically modified antisense RNA oligonucleotides using degradable poly(ethylene glycol) (PEG)-based hydrogels as a promising cancer therapy.19 Zhang and co-workers successfully employed chitosan and β-glycerophosphate-based magnetic hydrogels for sustained delivery of the BCG vaccine in the treatment of bladder cancer in female Wistar rats.20 Baeza and co-workers utilized the thermo-responsive copolymer of poly(ethyleneimine)-b-poly(N-isopropyl acrylamide) in combination with mesoporous silica and iron oxide nanoparticles as a platform for magnetic field induced drug release to combat multidrug resistance in cancer cells.21

Our group developed a poly (N-isopropyl acrylamide)-chitosan encapsulated Fe3O4 magnetic nanostructure (MNS)-based magnetic nanohydrogel (MNHG), which has been successful in combining cancer chemotherapeutics with non-invasive magnetic resonance imaging (MRI).22 The measured MRI T2 contrast (transverse spin relaxation) enhancement and the associated delivery efficacy of absorbed therapeutic cargo is shown Figure 1. Note that the hydrogel-MNS (HGMNS) system encapsulated with PEG functionalized Fe3O4 exhibits a higher relaxivity rate (r2) of 173 mM−1s−1 compared to 129 mM−1s−1 obtained for a hydrogel-MNS system encapsulated with POSS functionalized Fe3O4. The studies with PEG-functionalized HGMNS conjugated to doxorubicin (DOX) (Sigma Prod. No. D1515) have revealed a ~2-fold enhancement in drug release during 1 h RF (radio-frequency) field exposure followed by 24 h incubation at 37 °C. The enhanced release of therapeutic cargo in this case is attributed to microenvironmental heating in the surroundings as well as to the magneto-mechanical vibrations caused by high frequency RF inside the hydrogels. Also, RF-induced drug delivery studies with cervical cancer cell lines (HeLa) for PEG-functionalized HGMNS show more than 80% cell death. These results suggest that magnetic hydrogel system has in vivo theranostic potential given its high MR contrast enhancement, encapsulated MNS, and RF-induced localized therapeutic delivery.

 Schematic depicting the thermo-responsive collapse of the magnetic nanohydrogel

Figure 1. A) Schematic depicting the thermo-responsive collapse of the magnetic nanohydrogel due to RF exposure leading to the release of the therapeutic drug and B) MR contrast characteristics of magnetic nanohydrogel. The r2 is the slope of the straight-fit line drawn for 1/T2 vs. iron concentrations of the corresponding sample; T2-weighted phantom images at five serially diluted iron concentrations of the same samples.22

 

We have also explored the in vivo evaluation of thermo-responsive poly(N-isopropyl acrylamide)-chitosan based magnetic nanohydrogel (MNHG) in a subcutaneous fibrosarcoma tumor model for use in localized delivery of chemotherapeutics.23 For this, the biocompatibility and biodistribution of the MNHG was evaluated in Swiss mice, while efficacy in tumor growth inhibition was studied under the influence of an AC magnetic field (AMF). The ex vivo time-dependent pattern of accumulated MNHG in vital organs like lung, liver, spleen, kidney, and brain was also investigated. The tumor-bearing mice were subjected to hyperthermia by exposure to an RF magnetic field of 325 Oe operating at 265 kHz following intratumoral administration of dose I. The tumor size was measured at intervals of 72 h for a period of 2 weeks. The study revealed that the combinatorial therapy decelerated the growth of the tumor by ~3-fold (size; 1,545 } 720 mm3) as compared to the uninhibited exponential growth of the tumor (size; 4,510 } 735 mm3) in control mice. These results clearly demonstrate that MNHGs have significant potential for use as platforms for combined thermo-chemotherapy.

Tc-tuned Magnetic Nanovesicles

Magnetic nanovesicles containing paclitaxel (Sigma Prod. No. T7402) and a dextran-coated biphasic suspension of La0.75Sr0.25MnO3 and Fe3O4 magnetic nanoparticles were developed for use in chemotherapy and self-controlled (Tc tuned) hyperthermia.24

Sequential release of paclitaxel at 37 °C for 1 h followed hyperthermic heating at 44 °C for another 1 h (as expected for intratumoral injection) results in cumulative toxicity toward the cancer cells. Figure 2 shows that under exposure to AMF, the temperature remains controlled at 44 °C and a synergistic cytotoxicity of paclitaxel and hyperthermia is observed in MCF-7 cells. This indicates that magnetic nanovesicles containing biphasic suspension of La0.75Sr0.25MnO3 and Fe3O4 nanoparticles encapsulating paclitaxel have potential for combined self-controlled hyperthermia and chemotherapy.

Transmission electron micrographs of magnetic liposomes containing biphasic suspension

Figure 2. A) Transmission electron micrographs of magnetic liposomes containing biphasic suspension of La0.75Sr0.25MnO3 and Fe3O4 nanoparticles in 10:1 ratio. Inset (B, C, D) shows the diffraction pattern of magnetic liposomes, transmission electron microscopy image of a blank liposome, and diffraction pattern of a blank liposome. E) Cellular toxicity of MCF-7 cell line during hyperthermia experiments. F) The temperature profile during the hyperthermia experiment, as well as only for the AC magnetic field.24

Dendrimer-functionalized Magnetic Nanoparticles

Dendrimers are a class of hyper-branched symmetrical polymers that originate from a central core with repetitive branching units. Due to their structural properties and controlled size, dendrimers have emerged as an attractive material for biomedical applications, particularly as carriers for therapeutic cargos. Recently, there have been attempts to combine the unique features of dendrimer chemistry with the versatility of magnetic nanoparticles to provide a platform for enhanced therapeutics and biomedical applications.25 For example, Rouhollah and co-workers combined magnetic nanoparticles with different generations of polyamidoamine (PAMAM) dendrimers (Aldrich Prod. Nos. 664138 and 664049) to develop pH-responsive platforms and deliver doxorubicin to resistant breast cancer (MCF-7) cells.26 Yalcin and co-workers used PAMAM-coated magnetic nanoparticles to deliver the anticancer drug gemcitabine and retinoic acid to pancreatic cancer and stellate cells, successfully eliminating the cancer cells.27 Boni and co-workers used amphiphilic PAMAM in combination with hydrophobic iron oxide nanoparticles to study relaxivity for MRI applications.28 We recently developed dendrimer-conjugated iron oxide nanoparticles and explored the potential therapeutic efficiency of PAMAM-Fe3O4-DOX triads.13 Different generations (G) (G3, G5, and G6) of PEG-PAMAMs were used to modify the surface of glutamic acid conjugated Fe3O4 nanoparticles (Figure 3). The biodistribution and biocompatibility of these DOX-loaded dendritic magnetic nanoparticles in C57BL/6 black mice are currently under investigation.

 Illustration of the synthetic procedure for the synthesis

Figure 3. Illustration of the synthetic procedure for the synthesis of PAMAM-Fe3O4-DOX triads and their application in pH-responsive drug delivery.13

 

Lipid-coated Mesoporous Magnetic Nanoassemblies

Lipid-based vesicles have attracted much interest in biomedical applications. Their tailorable composition, size, chemical properties, and ability to encapsulate drugs make lipids the first choice as delivery vectors. Results from Nappini and co-workers reveal that a low frequency alternating magnetic field can be utilized as the external stimuli to release drug molecules from lipid coated magnetic nanoparticles.29 Park and co-workers have combined hyaluronic acid-based liposomes with commercially available magnevist as a platform for the delivery of doxorubicin to breast cancer cells and MRI of tumors.30 In fact, the use of magnetic liposomes in gene delivery has also been reported. Recently, cholesterol and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)-based liposomes have been used by Jiang and co-workers to encapsulate iron oxide nanoparticles for the delivery of the gWiz-GFP plasmid DNAencoding green fluorescent protein (GFP).31 A new pH- and thermosensitive drug delivery system consisting of a thin lipid (Sigma Prod. No. P0763) layer encapsulating mesoporous magnetite nanoassemblies (LMMNA) has been developed by our group (Figure 4). These LMMNAs are capable of carrying and delivering two anticancer drugs, namely hydrophilic doxorubicin hydrochloride (DOX) and hydrophobic paclitaxel (TXL), simultaneously.14 This hybrid system also acts as a heating platform when exposed to an AMF and exhibits a very high loading efficiency. The experiments reveal an improved in vitro cytotoxic effect when both drugs are delivered simultaneously in cervical cancer (HeLa), breast cancer (MCF‑7), and liver cancer (HepG2) cells. The application of an AMF for 10 min substantially improves the cell killing efficiency due to the simultaneous thermo and chemotherapy.

Illustration of pH-sensitive and thermosensitive LMMNA as a dual drug delivery system containing doxorubicin

Figure 4. A) Illustration of pH-sensitive and thermosensitive LMMNA as a dual drug delivery system containing doxorubicin (DOX) and paclitaxel (TXL). Drug release is triggered by an AC magnetic field applied to the tumor cells (B) in vivo biodistribution and thermo-chemotherapy studies controlled through fluorescence imaging.14

 

LMMNAs are currently under investigation as a dual drug delivery system for in vivo biodistribution and thermo-chemotherapy studies in subcutaneous tumor-bearing nude mice through fluorescence bioimaging. The biodistribution of these non-targeted nanoparticles is being studied in non-tumored nude mice by optical fluorescence imaging and measurement of Fe concentration in different vital organs. Biodistribution studies show a greater accumulation of lipid-coated magnetic nanoparticles in the large intestine, lung, liver, spleen, and stomach than in the kidney and heart. Tumor regression was also monitored by bioluminescence imaging as well as repeated fluorescence imaging due to the organ uptake of LMMNA-DOX:TXL. The combination therapy using an AC magnetic field with dual chemotherapeutics is currently under investigation in combating tumors in mice models.

Summary and Future Prospects

Multifunctional ferrofluids are one of the most intensively investigated functional nanomaterials for biomedical applications. The potential of external magnetic fields to manipulate the nanoparticles has enhanced their individual advantages in the direction of targeted chemotherapeutics, diagnostics and imaging of cancer. Multifunctionalized ferrofluids have been shown to offer improved cancer treatment and disease management. Research with multifunctional ferrofluids has moved forward from preliminary in vitro studies to a promising in vivo stage.

 

Materials

     

References

  1. Cordova, G.; Attwood, S.; Gaikawad, R.; GuF.; Leonenko, Z. Nano Biomed. Eng. 2014, 6, 31.
  2. Hasany, S. F.; Abdurahman, N. H.; Sunarti, A. R.; Jose, R. Current Nanoscience 2013, 9, 561.
  3. Xie, J.; Jon, S. Theranostics 2012, 2, 122.
  4. Laurent, S.; Forge, D.; Port, M.; Roch, A.; Robic, C.; Elst, L. V.; Muller, R. N. Chem. Rev. 2008, 108, 2064.
  5. Shokrollahi, H. Materials Science and Engineering: C 2013, 33, 2476–2487.
  6. Chandra, S.; Barick, K. C.; Bahadur, D. Advanced Drug Delivery Reviews 2011, 63, 1267–1281.
  7. Mornet, S.; Portier, J.; Duguet, E. Journal of Magnetism and Magnetic Materials 2005, 293, 127–134.
  8. Hong, R. Y.; Pan, T. T.; Li, H. Z. Journal of Magnetism and Magnetic Materials 2006, 303, 60–68.
  9. Rosensweig, R. E. Journal of Magnetism and Magnetic Materials 2002, 252, 370–374.
  10. Laurent, S.; Dutz, S.; Hafeli, U. O.; Mahmoudi, M. Advances in Colloid and Interface Science 2011, 166, 8–23.
  11. Love, R.; Soriano, R. Z.; Walsh, R. J. Cancer Research 1970, 30, 1525–1533.
  12. Jordan, A.; Scholz, R.; Wust, P.; Fahling, H.; Roland, F. Journal of Magnetism and Magnetic Materials 1999, 201, 413–419.
  13. Nigam, S.; Chandra, S.; Newgreen, D. F.; Bahadur, D.; Chen, Q. Langmuir 2014, 30, 1004–1011.
  14. Pradhan, L.; Srivastava, R.; Bahadur, D. Acta Biomaterialia 2014, 10, 2976–2987.
  15. Jaiswal, M. K.; Banerjee, R.; Pradhan, P.; Bahadur, D. Colloids and Surfaces B: Biointerfaces 2010, 81, 185–194.
  16. Nigam, S.; Barick, K. C.; Bahadur, D. Journal of Magnetism and Magnetic Materials 2011, 323, 237–243.
  17. Singh, N. S.; Hrishikesh, K.; Lina, P.; Bahadur, D. Nanotechnology 2013, 24, 065101.
  18. Li, Y.; Huang, G.; Zhang, X.; Li, B.; Chen, Y.; Lu, T.; Lu, T. J.; Xu, F. Advanced Functional Materials 2013, 23, 660–672.
  19. Lin, C.-W.; Tseng, S. J.; Kempson, I. M.; Yang, S.-C.; Hong, T.-M.; Yang, P.-C. Biomaterials 2013, 34, 4387–4393.
  20. Zhang, D.; Sun, P.; Li, P.; Xue, A.; Zhang, X.; Zhang, H.; Jin, X. Biomaterials 2013, 34, 10258–10266.
  21. Baeza, A.; Guisasola, E.; Ruiz-Hernandez, E.; Vallet-Regi, M. Chemistry of Materials 2012, 24, 517–524.
  22. Jaiswal, M. K.; De, M.; Chou, S. S.; Vasavada, S.; Bleher, R.; Prasad, P. V.; Bahadur, D.; Dravid, V. P. ACS Applied Materials & Interfaces 2014, 6, 6237–6247.
  23. Jaiswal, M. K.; Gogoi, M.; Dev Sarma, H.; Banerjee, R.; Bahadur, D. Biomaterials Science 2014, 2, 370–380.
  24. Gogoi, M.; Sarma, H. D.; Bahadur, D.; Banerjee, R. Nanomedicine 2013, 9, 955–970.
  25. Chandra, S.; Nigam, S.; Bahadur, D. Journal of Biomedical Nanotechnology 2014, 10, 32–49.
  26. Rouhollah, K.; Pelin, M.; Serap, Y.; Gozde, U.; Ufuk, G. Journal of Pharmaceutical Sciences 2013, 102, 1825–1835.
  27. Yalcın, S.; Erkan, M.; Unsoy, G.; Parsian, M.; Kleeff, J.; Gunduz, U. Biomedicine & Pharmacotherapy 2014, 68, 737–743.
  28. Boni, A.; Albertazzi, L.; Innocenti, C.; Gemmi, M.; Bifone, A. Langmuir 2013, 29, 10973–10979.
  29. Nappini, S.; Bonini, M.; Bombelli, F. B.; Pineider, F.; Sangregorio, C.; Baglioni, P.; Norden, B. Soft Matter 2011, 7, 1025–1037.
  30. Park, J.-H.; Cho, H.-J.; Yoon, H. Y.; Yoon, I.-S.; Ko, S.-H.; Shim, J.-S.; Cho, J.-H.; Park, J. H.; Kim, K.; Kwon, I. C.; Kim, D.-D. Journal of Controlled Release 2014, 174, 98–108.
  31. Jiang, S.; Eltoukhy, A. A.; Love, K. T.; Langer, R.; Anderson, D. G. Nano Letters 2013, 13, 1059–1064.

 

Related Links